Hemogenyx Pharmaceuticals Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
16
- Stock Symbol
-
HEMO
- Investments
-
1
- Share Price
-
$8.28
- (As of Thursday Closing)
Hemogenyx Pharmaceuticals General Information
Description
Hemogenyx Pharmaceuticals PLC is clinical-stage biotechnology focused on the discovery, development and commercialisation of treatments relating to the treatment of blood cancers, certain solid cancers, autoimmune diseases, and viral infections. The products under development are designed to address a range of problems that occur with current standard of care treatments. The Group has one reportable segment, the discovery, development, and commercialisation of treatments relating to blood and immune system disorders and viral infections, and administrative functions in the United Kingdom. It has its presence in United Kingdom; and United States.
Contact Information
Website
www.hemogenyx.comCorporate Office
- 6 Heddon Street
- London W1B 4BT
- England, United Kingdom
Corporate Office
- 6 Heddon Street
- London W1B 4BT
- England, United Kingdom
Hemogenyx Pharmaceuticals Timeline
Hemogenyx Pharmaceuticals Stock Performance
As of 12-Nov-2026, Hemogenyx Pharmaceuticals’s stock price is $8.28. Its current market cap is $57.1M with 6.9M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $8.28 | $8.27 | $4.74 - $16.54 | $57.1M | 6.9M | 23.6K | -$1.76 |
Hemogenyx Pharmaceuticals Financials Summary
As of 30-Jun-2026, Hemogenyx Pharmaceuticals has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 68,436 | 49,132 | 19,191 | 34,611 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (14,240) | (11,789) | (6,054) | (7,235) |
| Net Income | (15,177) | (12,856) | (7,180) | (8,317) |
| Total Assets | 9,108 | 5,623 | 5,285 | 7,778 |
| Total Debt | 2,458 | 2,699 | 3,291 | 3,753 |
Hemogenyx Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Hemogenyx Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Hemogenyx Pharmaceuticals Comparisons
Industry
Financing
Details
Hemogenyx Pharmaceuticals Competitors (5)
One of Hemogenyx Pharmaceuticals’s 5 competitors is Quell Therapeutics, a Venture Capital-Backed company based in London, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Quell Therapeutics | Venture Capital-Backed | London, United Kingdom | ||||
| Prokarium | Venture Capital-Backed | London, United Kingdom | ||||
| Autolus | Formerly VC-backed | London, United Kingdom | ||||
| Pathios Therapeutics | Venture Capital-Backed | Abingdon, United Kingdom | ||||
| Cabaletta Bio | Formerly VC-backed | Philadelphia, PA |
Hemogenyx Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Hemogenyx Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Hemogenyx Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Hemogenyx Pharmaceuticals Acquisitions (1)
Hemogenyx Pharmaceuticals’s most recent deal was a Merger/Acquisition with Silver Falcon. The deal was made on 08-Oct-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Silver Falcon | 08-Oct-2017 | Merger/Acquisition | Pharmaceuticals |
Hemogenyx Pharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Hemogenyx Pharmaceuticals FAQs
-
When was Hemogenyx Pharmaceuticals founded?
Hemogenyx Pharmaceuticals was founded in 2013.
-
Where is Hemogenyx Pharmaceuticals headquartered?
Hemogenyx Pharmaceuticals is headquartered in London, United Kingdom.
-
What is the size of Hemogenyx Pharmaceuticals?
Hemogenyx Pharmaceuticals has 16 total employees.
-
What industry is Hemogenyx Pharmaceuticals in?
Hemogenyx Pharmaceuticals’s primary industry is Biotechnology.
-
Is Hemogenyx Pharmaceuticals a private or public company?
Hemogenyx Pharmaceuticals is a Public company.
-
What is Hemogenyx Pharmaceuticals’s stock symbol?
The ticker symbol for Hemogenyx Pharmaceuticals is HEMO.
-
What is the current stock price of Hemogenyx Pharmaceuticals?
As of 12-Nov-2026 the stock price of Hemogenyx Pharmaceuticals is $8.28.
-
What is the current market cap of Hemogenyx Pharmaceuticals?
The current market capitalization of Hemogenyx Pharmaceuticals is $57.1M.
-
Who are Hemogenyx Pharmaceuticals’s competitors?
Quell Therapeutics, Prokarium, Autolus, Pathios Therapeutics, and Cabaletta Bio are competitors of Hemogenyx Pharmaceuticals.
-
What is Hemogenyx Pharmaceuticals’s annual earnings per share (EPS)?
Hemogenyx Pharmaceuticals’s EPS for 12 months was -$1.76.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
